212 related articles for article (PubMed ID: 38572783)
1. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Ren S; Feng L; Liu H; Mao Y; Yu Z
Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
[TBL] [Abstract][Full Text] [Related]
2. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
3. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
4. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
5. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Huang J; Liu D; Wang Y; Liu L; Li J; Yuan J; Jiang Z; Jiang Z; Hsiao WW; Liu H; Khan I; Xie Y; Wu J; Xie Y; Zhang Y; Fu Y; Liao J; Wang W; Lai H; Shi A; Cai J; Luo L; Li R; Yao X; Fan X; Wu Q; Liu Z; Yan P; Lu J; Yang M; Wang L; Cao Y; Wei H; Leung EL
Gut; 2022 Apr; 71(4):734-745. PubMed ID: 34006584
[TBL] [Abstract][Full Text] [Related]
6. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
[TBL] [Abstract][Full Text] [Related]
7. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
8. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.
Shaikh FY; Gills JJ; Mohammad F; White JR; Stevens CM; Ding H; Fu J; Tam A; Blosser RL; Domingue JC; Larman TC; Chaft JE; Spicer JD; Reuss JE; Naidoo J; Forde PM; Ganguly S; Housseau F; Pardoll DM; Sears CL
Cancer Immunol Immunother; 2022 Oct; 71(10):2405-2420. PubMed ID: 35217892
[TBL] [Abstract][Full Text] [Related]
9. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
[TBL] [Abstract][Full Text] [Related]
10. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
11. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
12. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota and its metabolites in non-small cell lung cancer and brain metastasis: from alteration to potential microbial markers and drug targets.
Jiang H; Zeng W; Zhang X; Li Y; Wang Y; Peng A; Cao D
Front Cell Infect Microbiol; 2023; 13():1211855. PubMed ID: 38304459
[TBL] [Abstract][Full Text] [Related]
14. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
[TBL] [Abstract][Full Text] [Related]
15.
Tomita Y; Goto Y; Sakata S; Imamura K; Minemura A; Oka K; Hayashi A; Jodai T; Akaike K; Anai M; Hamada S; Iyama S; Saruwatari K; Saeki S; Takahashi M; Ikeda T; Sakagami T
Oncoimmunology; 2022; 11(1):2081010. PubMed ID: 35655708
[TBL] [Abstract][Full Text] [Related]
16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
17. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638308
[No Abstract] [Full Text] [Related]
18. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Xin Y; Liu CG; Zang D; Chen J
Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
[TBL] [Abstract][Full Text] [Related]
20. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.
Sarkar J; Cortes Gomez E; Oba T; Chen H; Dy GK; Segal BH; Ernstoff MS; Ito F
World J Oncol; 2023 Jun; 14(3):178-187. PubMed ID: 37350807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]